脾多肽注射液联合盐酸氨溴索治疗慢性阻塞性肺疾病急性加重期临床观察

Spleen Polypeptide Injection Combined with Ambroxol Hydrochloride Injection on Patients with AECOPD

目的探讨脾多肽注射液联合盐酸氨溴索治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及对免疫功能和炎性反应的影响。方法选取医院2016年6月至2018年12月收治的AECOPD患者112例,按随机数字表法分为对照组和观察组,各56例。两组患者均予常规治疗及盐酸氨溴索注射液,观察组患者加用脾多肽注射液。结果观察组总有效率为78. 57%,显著高于对照组的57. 14%(P <0. 05)。与治疗前比较,两组患者治疗后的CD3+和CD4+水平及CD4+/CD8+均显著升高,CD8+水平及白细胞介素6(IL-6)、白细胞介素8(IL-8)、肿瘤坏死因子-α(TNF-α)、可溶性白细胞介素2受体(SIL-2R)水平均显著降低(P <0. 05),且观察组患者上述指标改善程度均显著优于对照组(P <0. 05)。观察组与对照组不良反应发生率相当(10. 71%比7. 14%,P> 0. 05)。结论脾多肽注射液联合盐酸氨溴索治疗AECOPD疗效较好,可改善患者的免疫功能及炎性因子水平。

Objective To investigate the efficacy of spleen polypeptide injection combined with ambroxol hydrochloride injection on immune function and inflammatory reaction in patients with acute exacerbation of chronic obstructive pulmonary disease( AECOPD).Methods A total of 112 patients with AECOPD treated in the hospital from June 2016 to December 2018 were selected and divided into control group and observation group according to random number table method,56 cases in each group. Both groups were treated with ambroxol hydrochloride injection,while the observation group was added with spleen polypeptide injection. Results The total effective rate in the observation group was 78. 57 %,which was significantly higher than 57. 14 % in the control group( P < 0. 05).Compared with before treatment,the level of CD3+,CD4+,CD4+/CD8+in the two groups significantly increased,and the levels of CD8+,interleukin-6( IL-6),interleukin-8( IL-8),tumor necrosis factor-α( TNF-α),soluble interleukin-2( SIL-2 R) in the two groups significantly decreased( P < 0. 05),and the improvements of the indexes in the observation group were significantly better than those in the control group( P < 0. 05). There was no difference in the incidence of adverse reactions between the two groups( 10. 71% vs. 7. 14%,P > 0. 05). Conclusion Spleen polypeptide injection combined with ambroxol hydrochloride injection is effective in treating AECOPD,which can improve the immune function and the level of inflammatory factors.